XML 94 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Benefit Plans and Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Intrinsic Value of Options Exercised and Fair Value of Options Vested
The total intrinsic value of stock options exercised as of the date of exercise was as follows:
 
Twelve Months Ended
December 31,
(In millions)
2019
 
2018
 
2017
Intrinsic value of options exercised
$
7.4

 
$
30.0

 
$
21.6
Schedule of Restricted Stock Units Activity A summary of our RSU activity for the twelve months ended December 31, 2019, 2018 and 2017 is as follows:
(In millions except weighted average grant date fair value)
Shares
 
Weighted 
Average
Grant Date
Fair Value
 
Aggregate
Intrinsic Value
Nonvested at December 31, 2016
3.7

 
$
62.51

 
 
Granted
1.3

 
75.78

 
 
Vested
(1.9
)
 
58.92

 
 
Forfeited
(0.4
)
 
67.97

 
 
Nonvested at December 31, 2017
2.7

 
70.68

 
$
154.5

Granted
1.7

 
66.07

 
 
Vested
(1.4
)
 
68.44

 
 
Forfeited
(0.3
)
 
68.56

 
 
Nonvested at December 31, 2018
2.7

 
69.19

 
319.0

Granted
0.7

 
144.37

 
 
Vested
(1.4
)
 
69.45

 
 
Forfeited
(0.2
)
 
83.45

 
 
Nonvested at December 31, 2019
1.8

 
$
96.63

 
$
392.0
Schedule of Stock Options Reserved for Future Issuance
Shares of common stock reserved for future issuance were as follows as of the dated indicated:
 
December 31,
(In millions)
2019
 
2018
Stock options and awards under our plans:
 
 
 
Stock options granted and outstanding
—

 
0.1

Unvested restricted stock units
1.8

 
2.7

Reserved for future grant
4.9

 
3.2

Employee Stock Purchase Plan
0.9

 
1.1

Total
7.6

 
7.1
Schedule of Share-Based Compensation Expenses
The following table summarizes share-based compensation expense related to restricted stock units and employee stock purchases under the ESPP for the twelve months ended December 31, 2019, 2018 and 2017:
 
Twelve Months Ended
December 31,
(In millions)
2019
 
2018
 
2017
Cost of sales
$
9.0

 
$
9.2

 
$
9.6

Research and development
33.5

 
33.0

 
37.5

Selling, general and administrative
60.2

 
59.7

 
59.1

Total share-based compensation expense included in net loss
$
102.7

 
$
101.9

 
$
106.2
Schedule of Valuation Assumptions for Employee Stock Purchase Plan
We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.
 
Twelve Months Ended
December 31,
 
2019
 
2018
 
2017
Risk free interest rate
1.72 - 2.55

 
1.55 – 2.25

 
0.75 – 1.12

Dividend yield
—
%
 
—
%
 
—
%
Expected volatility of DexCom common stock
0.40 - 0.51

 
0.50 – 0.67

 
0.33 – 0.56

Expected life (in years)
1

 
1

 
1